Business ❯ Pharmaceuticals

Biotechnology

Drug Development Acquisitions Mergers and Acquisitions Clinical Trials Partnerships Clinical Development Biosimilars Vaccine Development Moderna Cancer Treatment

FDA Approves Corcept’s Lifyorli for Platinum-Resistant Ovarian Cancer

The decision adds a new option in a hard-to-treat cancer with modest survival gains.

Sarepta Shares First Clinical Data From siRNA Trials in FSHD1 and DM1

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

Trump Promotes Drug-Price Push and Reshoring on Cincinnati-Area Swing, Backs Massie Challenger

Xenon to Present Topline X-TOLE2 Phase 3 Results in Focal Onset Seizures at 8 A.M. ET Today

Novo Nordisk Licenses Vivtex Platform in $2.1 Billion Push for Oral Obesity and Diabetes Drugs

Astellas–Vir Prostate Cancer Alliance Launches With New Data as VIR Stock Surges

Viking Therapeutics' Obesity Drug Moves Into Phase 3 as Investors Weigh Upside

Telangana Unveils Life Sciences GCC Zone in Bharat Future City as BioAsia 2026 Yields New Investments

Eli Lilly to Acquire Orna Therapeutics in Up to $2.4 Billion Bet on In Vivo CAR‑T

CSL CEO Paul McKenzie Exits Immediately as Board Installs Veteran Gordon Naylor as Interim Chief

Lilly, Repertoire Strike Up-to-$1.93 Billion Autoimmune Drug Pact

Lilly Strikes Up to $1.12 Billion Pact With Seamless Therapeutics for Hearing‑Loss Gene Editing

Insilico, Qilu Strike Near-$120 Million AI Drug Discovery Pact for Cardiometabolic Therapies

De La Soul Launches Good Health Summit at Morehouse on Feb. 19

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

ImmunityBio Sets 30-Day FDA Submission After Positive Meeting on Anktiva Expansion

Novo Nordisk Expands Aspect Partnership, Transfers Diabetes Cell Tech as Aspect Takes Lead

Epcoritamab Improves PFS but Not OS in Phase 3 DLBCL Trial

AnaptysBio CMO Trims Stake After Option Exercise as Director Reports Separate Sale